Zeynep Eroglu

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam et al. · Annals of Oncology · 2016 · 823 citations · Full text

Life Sciences, Immunology, Oncology +17

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Megan H. Pollack, Helen Clare Dearden, K. Rapazzo et al. · Annals of Oncology · 2017 · 392 citations · Full text

Pharmacy, Immunology, Oncology +14

RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Amanpreet Kaur, Marie R. Webster, Katie Marchbank et al. · Nature · 2016 · 390 citations

Medicine, Cancer Biology, Oncology +14

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies

Alain P. Algazi, Katy K. Tsai, Alexander N. Shoushtari et al. · Cancer · 2016 · 378 citations

Medicine, Oncology, Pharmacology +17

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster et al. · Clinical Cancer Research · 2018 · 361 citations · Full text

Medicine, Immunology, Oncology +17